Article
Oncology
Sebastien Thureau, Nicolas Piton, Pierrick Gouel, Romain Modzelewski, Antoine Dujon, Jean-Marc Baste, Jean Melki, Philippe Rinieri, Christophe Peillon, Olivier Rastelli, Justine Lequesne, Sebastien Hapdey, Jean-Christophe Sabourin, Pierre Bohn, Pierre Vera
Summary: This study compared the effectiveness of two hypoxia tracers, FMISO and FAZA, for defining hypoxic volumes in lung cancers before surgery. The results showed that FMISO was superior to FAZA in this regard, with both tracers correlating well with hypoxia in the tumors.
Article
Multidisciplinary Sciences
Pauline Bourigault, Michael Skwarski, Ruth E. Macpherson, Geoff S. Higgins, Daniel R. McGowan
Summary: This study investigated the correlation between 2-hour and 4-hour post-injection FMISO-PET imaging in NSCLC patients and found that imaging at 4 hours after injection provided better results. There was a strong correlation between the results of the 2-hour and 4-hour scans in overall tumors, but the correlation decreased from the center to the edge in tumor subregions.
SCIENTIFIC REPORTS
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Sang Woo Lee, Seong-Jang Kim
Summary: This study evaluated the diagnostic accuracies of dual-time-point F-18-FDG PET/CT for detecting metastatic mediastinal lymph nodes in NSCLC patients. Results showed that dual-time-point F-18-FDG PET/CT exhibited good diagnostic performances for detecting metastatic mediastinal LNs, with retention index or %Delta SUVmax being superior to early or delayed images for detection of mediastinal LN metastasis.
CLINICAL NUCLEAR MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yong Han, Yuan Ma, Zhiyuan Wu, Feng Zhang, Deqiang Zheng, Xiangtong Liu, Lixin Tao, Zhigang Liang, Zhi Yang, Xia Li, Jian Huang, Xiuhua Guo
Summary: This study evaluated the capability of PET/CT images for differentiating histologic subtypes of NSCLC and identified the optimal model from radiomics-based machine learning/deep learning algorithms. Linear discriminant analysis and support vector machine coupled with feature selection method achieved optimal performance for the classification of ADC and SCC. The VGG16 deep learning algorithm outperformed conventional machine learning methods in combination with radiomics for the differential diagnosis of NSCLC subtypes.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Medicine, General & Internal
Jianhua Qin, Yu Tang, Bao Wang
Summary: This study explores the feasibility of generating regional F-18-fluoromisonidazole (F-18-FMISO) positron emission tomography (PET) images using advanced magnetic resonance (MR) images and their predictive value for survival in glioblastoma patients. It demonstrates that multiple advanced MR images can be used to generate qualified regional F-18-FMISO PET images using neural networks. The generated images have predictive value in the prognostic evaluation of glioblastoma.
Article
Oncology
Chae Hong Lim, Soo Bin Park, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Yong Chan Ahn, Myung-ju Ahn, Joon Young Choi
Summary: This study evaluated the diagnostic value of FDG PET/CT surveillance for detecting clinically unsuspected recurrence or SPC in NSCLC patients after curative therapy. It found that surveillance PET/CT showed good diagnostic efficacy, especially in certain subgroups of patients.
Article
Oncology
Anine Larsen Ottestad, Hakon Johansen, Tarje Onsoien Halvorsen, Hong Yan Dai, Sissel Gyrid Freim Wahl, Elisabeth Fritzke Emdal, Bjorn Henning Gronberg
Summary: This study investigated the association between circulating tumor DNA (ctDNA) levels and tumor metabolic activity in early-stage non-small cell lung cancer (NSCLC) patients. The results showed a positive correlation between ctDNA quantity and tumor metabolic parameters. Furthermore, ctDNA detection was found to be an independent negative prognostic factor.
Article
Medicine, General & Internal
Sara Pellegrino, Rosa Fonti, Armin Hakkak Moghadam Torbati, Roberto Bologna, Rocco Morra, Vincenzo Damiano, Elide Matano, Sabino De Placido, Silvana Del Vecchio
Summary: We investigated the role of Coefficient of Variation (CoV) derived from F-18-FDG PET/CT in the prognosis of NSCLC patients. Our retrospective study included 84 advanced NSCLC patients who underwent F-18-FDG PET/CT before therapy. We found that CoV, by reflecting the heterogeneity of glycolytic phenotype, can predict clinical outcomes in NSCLC patients.
Article
Oncology
Preetha Aravind, Sanjay Popat, Tara D. Barwick, Neil Soneji, Mark Lythgoe, Katherina B. Sreter, Jingky P. Lozano-Kuehne, Mattias Bergqvist, Neva Patel, Eric O. Aboagye, Laura M. Kenny
Summary: This study aimed to investigate the early drug action of the antifolate drug pemetrexed on thymidylate synthase (TS) inhibition using F-18-FLT PET/CT imaging. The results showed that patients who exhibited changes in the imaging biomarker had a better therapy response and longer overall survival. These findings suggest the potential use of F-18-FLT PET/CT in understanding the basis of drug action in studies involving TS inhibitors.
Article
Neurosciences
Yanxiao Li, Yee Ling Ng, Manish D. Paranjpe, Qi Ge, Fengyun Gu, Panlong Li, Shaozhen Yan, Jie Lu, Xiuying Wang, Yun Zhou
Summary: This study aimed to improve the statistical power in detecting changes in brain glucose metabolism, amyloid, and tau deposition in Alzheimer's disease studies by using a reference tissue-based quantification approach. The results showed that the tracer-specific reference tissue improved the detection of PET SUVR changes, which is beneficial for early diagnosis, disease progression monitoring, and therapeutic response in Alzheimer's disease.
HUMAN BRAIN MAPPING
(2022)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Keith L. Spinali, David J. Papke, Hina J. Shah
Summary: F-18-DCFPyl is used to detect recurrent or metastatic prostate cancer and can target nonprostatic disease entities that mimic prostate cancer. The interpreting physician needs to consider serum prostate-specific antigen levels and uptake distribution to avoid misdiagnosis of metastatic prostate cancer. We describe the association of F-18-DCFPyl uptake with a previously undescribed hepatic small vessel neoplasm.
CLINICAL NUCLEAR MEDICINE
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Xiaoqian Zhao, Yan Zhao, Jingmian Zhang, Zhaoqi Zhang, Lihua Liu, Xinming Zhao
Summary: This study aimed to evaluate the predictive power of PET/CT-based radiomics features in predicting PD-L1 expression status in NSCLC patients. Through analyzing 334 NSCLC patients who underwent [F-18]FDG PET/CT imaging, radiomics features were extracted and radiomics model, clinical model, and combined model were constructed. The results showed that the radiomics model had better predictive performance than the clinical model, and the combined model had higher AUC values, indicating that PET/CT-based radiomics features can be used to preselect patients who may benefit from PD-1/PD-L1-based immunotherapy.
Article
Endocrinology & Metabolism
Leilei Wu, Jingru Liu, Shasha Wang, Menglin Bai, Min Wu, Zhenhua Gao, Jianing Li, Jinming Yu, Jie Liu, Xue Meng
Summary: The study investigated the correlation of F-18-RGD uptake during PET with tumoral PD-L1 expression and explored its potential in immune checkpoint inhibitor treatment. Both mouse experiments and clinical studies showed that higher uptake of F-18-RGD correlated with depressed PD-L1 expression in tumor cells. SUVmax was found to be the best parameter for displaying tumor PD-L1 expression.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Julie Tanguy, Francoise Goirand, Alexanne Bouchard, Jame Frenay, Mathieu Moreau, Celine Mothes, Alexandra Oudot, Alex Helbling, Melanie Guillemin, Philippe Bonniaud, Alexandre Cochet, Bertrand Collin, Pierre-Simon Bellaye
Summary: IPF is a progressive disease with poor prognosis and limited treatment options. Hypoxia is a significant feature of IPF. This study demonstrated the potential of [F-18]FMISO PET imaging in predicting disease progression and treatment efficacy in preclinical models of lung fibrosis.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Oncology
Jianyuan Zhou, Sijuan Zou, Siyuan Cheng, Dong Kuang, Dan Li, Lixing Chen, Cong Liu, Jianhua Yan, Xiaohua Zhu
Summary: Through analyzing the correlations between metabolic parameters in DTP F-18-FDG PET images and tumor microenvironment immune types in patients with non-small cell lung cancer, it was found that high glucose metabolism correlated with TMIT-I tumors. A composite metabolic signature (Meta-Sig) and a combined model based on clinical and metabolic information showed improved performance in identifying patients who may respond to immunotherapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
M. J. E. Greuter, J. J. Eertink, G. Jongeneel, U. Duehrsen, A. Huettmann, C. Schmitz, P. J. Lugtenburg, S. F. Barrington, N. G. Mikhaeel, L. Ceriani, E. Zucca, R. Carr, T. Gyorke, C. N. Burggraaff, H. C. W. de Vet, O. S. Hoekstra, J. M. Zijlstra, V. M. H. Coupe
Summary: Guideline recommendations for diffuse large-B-cell lymphoma (DLBCL) treatment are shifting towards shorter treatment duration, but it is unclear whether shortening treatment duration causes harm. Using a Markov model, this study evaluated the cost-effectiveness of shortening treatment duration based on I-PET results, showing that it is justified to shorten treatment duration for I-PET negative patients but not for I-PET positive patients as it has harmful consequences.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)
Article
Biochemistry & Molecular Biology
Sander Bach, Birgit M. M. Wever, Mark A. van de Wiel, Joris D. Veltman, Sayed M. S. Hashemi, Geert Kazemier, Idris Bahce, Renske D. M. Steenbergen
Summary: This study investigated the circadian variation of urinary cfDNA abundance and methylation levels of cancer-associated genes in NSCLC patients. It found that men had significantly lower cfDNA concentrations and the variability in cfDNA levels between and within subjects was comparable with an ICC of 0.49. The study also found that the reproducibility of methylation markers varied considerably, ranging from 0.14 to 0.74, emphasizing the importance of collecting multiple samples per patient to improve test reproducibility.
Review
Immunology
Maarten M. Steinz, Aiarpi Ezdoglian, Fatemeh Khodadust, Carla F. M. Molthoff, Madduri Srinivasarao, Philip S. Low, Gerben J. C. Zwezerijnen, Maqsood Yaqub, Wissam Beaino, Albert D. Windhorst, Sander W. Tas, Gerrit Jansen, Conny J. van der Laken
Summary: Non-invasive imaging modalities, particularly macrophage imaging with folate-based PET tracers, hold great promise in diagnostic and therapy response monitoring of autoimmune diseases.
FRONTIERS IN IMMUNOLOGY
(2022)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Adrienne H. Brouwers, Joyce van Sluis, Johannes H. van Snick, Carolina P. Schroder, Inge O. Baas, Ronald Boellaard, Andor W. J. M. Glaudemans, Ronald J. H. Borra, Adriaan A. Lammertsma, Rudi A. J. O. Dierckx, Charalampos Tsoumpas
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Review
Oncology
Wietske I. Luining, Matthijs C. F. Cysouw, Dennie Meijer, N. Harry Hendrikse, Ronald Boellaard, Andre N. Vis, Daniela E. Oprea-Lager
Summary: Imaging plays a crucial role in the accurate staging of prostate cancer, and targeting the prostate-specific membrane antigen (PSMA) protein has become of great clinical value. PSMA-based imaging techniques have shown superior detection rates compared to previous methods, and PSMA has also become a target for delivering radionuclide therapy. This review summarizes recent developments in nuclear medicine related to PSMA in prostate cancer diagnostics and targeted radionuclide therapy, highlighting the potential benefits of PSMA-positron emission tomography (PET) imaging and PSMA-based radioligand therapy in the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Article
Oncology
Lalitha K. Shankar, Erich Huang, Saskia Litiere, Otto S. Hoekstra, Larry Schwartz, Sandra Collette, Ronald Boellaard, Jan Bogaerts, Lesley Seymour, Elisabeth G. E. deVries
Summary: Currently, guidelines for PET with FDG-PET interpretation for therapy response in oncology involve visual evaluation of FDG-PET/CT scans. However, quantitative measurements of metabolic activity in tumors may be more useful. Guidelines based on such measurements have been proposed, but more analysis is needed for regular use.
CLINICAL CANCER RESEARCH
(2023)
Article
Endocrinology & Metabolism
Fiona Heeman, Denise Visser, Maqsood Yaqub, Sander Verfaillie, Tessa Timmers, Yolande A. L. Pijnenburg, Wiesje M. van der Flier, Bart N. M. van Berckel, Ronald Boellaard, Adriaan A. Lammertsma, Sandeep S. Golla
Summary: Alzheimer's disease is characterized by reduced cerebral blood flow. This study compared the precision of different methods for measuring cerebral blood flow and found that relative blood flow methods had better repeatability than absolute blood flow methods. The high precision of relative blood flow may be due to a compensatory effect of the extraction fraction.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Anne M. Smith, Nancy A. Obuchowski, Norman L. Foster, Gregory Klein, P. David Mozley, Adriaan A. Lammertsma, Richard L. Wahl, John J. Sunderland, Jean-Luc Vanderheyden, Tammie L. S. Benzinger, Paul E. Kinahan, Dean F. Wong, Eric S. Perlman, Satoshi Minoshima, Dawn Matthews
Summary: Standardized approach in acquiring amyloid PET images increases their value as disease and drug response biomarkers. The Quantitative Imaging Biomarkers Alliance amyloid PET biomarker committee developed and validated a profile to characterize and reduce the variability of SUVRs, increasing statistical power for these assessments.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jerney de Jongh, Nicki J. F. Verweij, Maqsood Yaqub, Christiaan J. van Denderen, Irene E. van der Horst-bruinsma, Joost C. J. Bot, Bouke J. H. Boden, Robert Hemke, Frank F. Smithuis, Willem F. Lems, Adriaan A. Lammertsma, Alexandre E. Voskuyl, Maarten Boers, Gerben J. C. Zwezerijnen, Conny J. van der Laken
Summary: Lesions detected on [F-18]fluoride PET scans often fall outside the scope of MRI and CR, with partial overlap with abnormalities seen on MRI (especially BME) and CR (especially ankylosis). PET activity shows the strongest association with BME on MRI and ankylosis on CR.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Oncology
Mehrdad Rakaee, Elio Adib, Biagio Ricciuti, Lynette M. Sholl, Weiwei Shi, Joao Alessi, Alessio Cortellini, Claudia A. M. Fulgenzi, Patrizia Viola, David J. Pinato, Sayed Hashemi, Idris Bahce, Ilias Houda, Ezgi B. Ulas, Teodora Radonic, Juha P. Vayrynen, Elin Richardsen, Simin Jamaly, Sigve Andersen, Tom Donnem, Mark M. Awad, David J. Kwiatkowski
Summary: This study developed a machine-learning-based approach to evaluate the association between tumor-infiltrating lymphocytes (TILs) and immune checkpoint inhibitor (ICI) therapy in lung cancer patients. The results showed that high levels of TILs were associated with ICI treatment response and could be used for patient selection and precision therapy guidance.
Article
Oncology
Gregory J. Riely, Egbert F. Smit, Myung-Ju Ahn, Enriqueta Felip, Suresh S. Ramalingam, Anne Tsao, Melissa Johnson, Francesco Gelsomino, Raymond Esper, Ernest Nadal, Michael Offin, Mariano Provencio, Jeffrey Clarke, Maen Hussain, Gregory A. Otterson, Ibiayi Dagogo-Jack, Jonathan W. Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul Wissel, Keith Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E. Johnson
Summary: The combination of encorafenib and binimetinib showed clinical efficacy and acceptable safety in patients with BRAF(V600E)-mutant metastatic NSCLC.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Wyanne A. Noortman, Nicolas Aide, Dennis Vriens, Lisa S. Arkes, Cornelis H. Slump, Ronald Boellaard, Jelle J. Goeman, Christophe M. Deroose, Jean-Pascal Machiels, Lisa F. Licitra, Renaud Lhommel, Alessandra Alessi, Erwin Woff, Karolien Goffin, Christophe Le Tourneau, Jocelyn Gal, Stephane Temam, Jean-Pierre Delord, Floris H. P. van Velden, Lioe-Fee de Geus-Oei
Summary: The study aimed to build and externally validate an [F-18]FDG PET radiomic model for predicting overall survival in patients with head and neck squamous cell carcinoma. Two multicentre datasets were used to train and validate the model, which included patients treated with preoperative afatinib. The radiomic model outperformed the clinical model in predicting overall survival.
Article
Oncology
Koichi Goto, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, Sang-We Kim, David Planchard, Myung-Ju Ahn, Egbert F. Smit, Adrianus Johannes de Langen, Maurice Perol, Elvire Pons-Tostivint, Silvia Novello, Hidetoshi Hayashi, Junichi Shimizu, Dong-Wan Kim, Chih-Hsi Kuo, James Chih-Hsin Yang, Kaline Pereira, Fu-Chih Cheng, Ayumi Taguchi, Yingkai Cheng, Wenqin Feng, Zenta Tsuchihashi, Pasi A. Janne
Summary: T-DXd demonstrates clinically meaningful responses in patients with previously treated HER2-positive non-small-cell lung cancer, with favorable safety at a dosage of 5.4 mg/kg.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Zofia Piotrowska, Daniel Shao-Weng Tan, Egbert F. Smit, Alexander I. Spira, Ross A. Soo, Danny Nguyen, Victor Ho-Fun Lee, James Chih-Hsin Yang, Vamsidhar Velcheti, John M. Wrangle, Mark A. Socinski, Marianna Koczywas, John E. Janik, Jeffrey Jones, Helena Alexandra Yu
Summary: This study demonstrates that Zipalertinib has encouraging antitumor activity in heavily pretreated patients with EGFR ex20ins-mutant NSCLC, with an acceptable safety profile and low frequency of high-grade diarrhea and rash.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Mostafa Roya, Samaneh Mostafapour, Philipp Mohr, Laura Providencia, Zekai Li, Johannes H. van Snick, Adrienne H. Brouwers, Walter Noordzij, Antoon T. M. Willemsen, Rudi A. J. O. Dierckx, Adriaan A. Lammertsma, Andor W. J. M. Glaudemans, Charalampos Tsoumpas, Riemer H. J. A. Slart, Joyce van Sluis
Summary: Recently, a new type of PET scanner with long axial field-of-view (LAFOV) has been introduced in clinical practice. Compared to conventional PET scanners, LAFOV scanners have a larger coverage and higher sensitivity, providing new opportunities for clinical applications, such as reducing scan time, decreasing the amount of radiotracer used, and using dynamic or parametric imaging. Emerging technologies like artificial intelligence and imaging with multiple radiotracers can further enhance the clinical application of LAFOV PET.